Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.
Jeremy L. Ramdial, MD
Advertisement
Articles by Jeremy L. Ramdial, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
3
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
4
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
5